A Study of Pentasa in Patients With Ulcerative Colitis

N/ACompletedNCT01104753

Ferring Pharmaceuticals338 enrolled

Overview

Confirmation of safety profile of Pentasa slow release tablets 500 mg in patients with ulcerative colitis (UC).

Study Type

OBSERVATIONAL

Enrollment

338

Conditions

Ulcerative Colitis

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients suffering from ulcerative colitis Exclusion Criteria: * Hypersensitivity to mesalazine, salicylates or to any excipient * Severe damage to liver or renal functions

Locations (30)

Hospital Brandýs n/Lab.

Brandýs nad Labem, Czechia

Outcomes

Primary Outcomes

Verify the safety profile

* Number of AEs/SAEs * Intensity and seriousness of reported AEs/SAEs

Time frame: 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.